HCV-TARGET is an international consortium of leading HCV investigators who have established a common research database and are conducting a longitudinal observational study to answer important questions about HCV therapy with direct acting antiviral agents.

Unique aspects

HCV-TARGET is unique for a variety of reasons. The study:

• Engages community-based HCV providers
• Leverages existing research infrastructure developed through the NIH CTSA program
• Standardizes data acquisition using CTSA open source database (REDCap)
• Has potential for rapid recruitment of patients being treated with newly approved antiviral regimens

Benefits

The HCV-TARGET study leverages existing infrastructure of partnered academic and industry sponsors to foster benefits including:

• Translational research opportunities
• FDA collaboration
• Biorepository, design and analysis, and regulatory core utilization
• Standardized data acquisition using CTSA open source database (REDCaP)
• Engaged community-based HCV providers
• Unique T2-T4 research and educational opportunities